Bank of New York Mellon’s Oasmia Pharmaceutical AB OASM Stock Holding History

Bank of New York Mellon’s Portfolio OASM Stock Details OASM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,450	Closed	-$12K	–	4453
2017 Q4	$12K	Buy	+13,450	New	+$13K	﹤0.01%	4326

Other funds holding OASM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of New York Mellon's OASM Position: Q1 2018 in Review

Bank of New York Mellon sold out of Oasmia Pharmaceutical AB (OASM) in Q1 2018, closing a stake of 13,450 shares — an estimated $12K sold.

Bank of New York Mellon first reported a position in OASM in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 4 funds tracked by Wall St. Rank hold OASM as of Q1 2018.

Bank of New York Mellon reported no remaining Oasmia Pharmaceutical AB position as of Q1 2018 after selling out during the quarter.
Bank of New York Mellon sold 13,450 Oasmia Pharmaceutical AB shares in Q1 2018, an estimated $12K.
Bank of New York Mellon first reported a position in Oasmia Pharmaceutical AB in Q4 2017 and held it in 1 quarter.
Bank of New York Mellon's Oasmia Pharmaceutical AB position peaked at $12K in Q4 2017.
4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q1 2018.

Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.